{"id":"birch-pollen-allergoid","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (itching, swelling, erythema)"},{"rate":null,"effect":"Oral allergy syndrome or local oral symptoms"},{"rate":null,"effect":"Systemic allergic reactions (mild to moderate)"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The allergoid is created by chemically modifying birch pollen proteins to reduce their allergenic potency while preserving immunogenicity. When administered in escalating doses, it trains the immune system to tolerate birch pollen exposure, shifting the immune response from IgE-mediated allergic reactions toward regulatory T cell responses and IgG-blocking antibodies. This mechanism underlies allergen immunotherapy (AIT) and aims to provide long-term clinical and immunological tolerance.","oneSentence":"Birch pollen allergoid is a modified birch pollen extract that induces immune tolerance to birch pollen allergens through gradual desensitization.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:27.073Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Birch pollen-induced allergic rhinitis and/or allergic asthma"}]},"trialDetails":[{"nctId":"NCT00118612","phase":"PHASE2","title":"Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen","status":"COMPLETED","sponsor":"Allergy Therapeutics","startDate":"2005-07-07","conditions":"Type I Hypersensitivity","enrollment":68},{"nctId":"NCT00263627","phase":"PHASE3","title":"Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2005-06","conditions":"Pollen Allergy","enrollment":253},{"nctId":"NCT01144429","phase":"PHASE2","title":"Dose Finding Study for Depigoid Birch: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma","status":"COMPLETED","sponsor":"Leti Pharma GmbH","startDate":"2010-06","conditions":"Allergic Rhinitis and/or Rhinoconjunctivitis +- Asthma, Immunotherapy, Allergen","enrollment":344},{"nctId":"NCT00118625","phase":"PHASE2","title":"Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine","status":"COMPLETED","sponsor":"Allergy Therapeutics","startDate":"2005-07","conditions":"Type I Hypersensitivity","enrollment":40},{"nctId":"NCT00107705","phase":"PHASE1","title":"Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing","status":"COMPLETED","sponsor":"Allergy Therapeutics","startDate":"2005-04","conditions":"Type I Hypersensitivity","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["specific immunotherapy"],"phase":"phase_3","status":"active","brandName":"Birch pollen allergoid","genericName":"Birch pollen allergoid","companyName":"Allergopharma GmbH & Co. KG","companyId":"allergopharma-gmbh-co-kg","modality":"Biologic","firstApprovalDate":"","aiSummary":"Birch pollen allergoid is a modified birch pollen extract that induces immune tolerance to birch pollen allergens through gradual desensitization. Used for Birch pollen-induced allergic rhinitis and/or allergic asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}